Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition

References

• Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. 2016. Ovarian cancer. Nat Rev Dis Primers. 2:16061. doi:10.1038/nrdp.2016.61.
   PubMed Web of Science ®Google Scholar
• Lupo B, Trusolino L. 2014. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. Biochim Biophys Acta. 1846:201–215. doi:10.1016/j.bbcan.2014.07.004.
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ, et al. 2009. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 361:123–134. doi:10.1056/NEJMoa0900212.
   PubMed Web of Science ®Google Scholar
• Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, Sridhara R, Lee E, Tzou A, Philip R, et al. 2015. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res. 21:4257–4261. doi:10.1158/1078-0432.CCR-15-0887.
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, et al. 2012. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 366:1382–1392. doi:10.1056/NEJMoa1105535.
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, et al. 2011. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12:852–861. doi:10.1016/S1470-2045(11)70214-5.
   PubMed Web of Science ®Google Scholar
• Schopf FH, Biebl MM, Buchner J. 2017. The HSP90 chaperone machinery. Nat Rev Mol Cell Biol. 18:345–360. doi:10.1038/nrm.2017.20.
   PubMed Web of Science ®Google Scholar
• Jacquemont C, Simon JA, D’Andrea AD, Taniguchi T. 2012. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. Mol Cancer. 11:26. doi:10.1186/1476-4598-11-26.
   PubMed Web of Science ®Google Scholar
• Stecklein SR, Kumaraswamy E, Behbod F, Wang W, Chaguturu V, Harlan-Williams LM, Jensen RA. 2012. BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation. Proc Natl Acad Sci USA. 109:13650–13655. doi:10.1073/pnas.1203326109.
   PubMed Web of Science ®Google Scholar
• Jiang J, Lu Y, Li Z, Li L, Niu D, Xu W, Liu J, Fu L, Zhou Z, Gu Y, et al. 2017. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery. Invest New Drugs. 35:251–259. doi:10.1007/s10637-016-0424-x.
   PubMed Web of Science ®Google Scholar
• He S, Smith DL, Sequeira M, Sang J, Bates RC, Proia DA. 2014. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer. Invest New Drugs. 32:577–586. doi:10.1007/s10637-014-0095-4.
   PubMed Web of Science ®Google Scholar
• Gomez-Casal R, Bhattacharya C, Epperly MW, Basse PH, Wang H, Wang X, Proia DA, Greenberger JS, Socinski MA, Levina V. 2015. The HSP90 inhibitor ganetespib radiosensitizes human lung adenocarcinoma cells. Cancers (Basel). 7:876–907. doi:10.3390/cancers7020814.
   PubMed Web of Science ®Google Scholar
• Lee H, Saini N, Howard EW, Parris AB, Ma Z, Zhao Q, Zhao M, Liu B, Edgerton SM, Thor AD, et al. 2018. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells. Sci Rep. 8:6829. doi:10.1038/s41598-018-25284-0.
   PubMed Web of Science ®Google Scholar
• Liu H, Xiao F, Serebriiskii IG, O’Brien SW, Maglaty MA, Astsaturov I, Litwin S, Martin LP, Proia DA, Golemis EA, et al. 2013. Network analysis identifies an HSP90-central hub susceptible in ovarian cancer. Clin Cancer Res. 19:5053–5067. doi:10.1158/1078-0432.CCR-13-1115.
   PubMed Web of Science ®Google Scholar
• Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, et al. 2018. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 379:753–763. doi:10.1056/NEJMoa1802905.
   PubMed Web of Science ®Google Scholar
• Liu X, Ory V, Chapman S, Yuan H, Albanese C, Kallakury B, Timofeeva OA, Nealon C, Dakic A, Simic V, et al. 2012. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol. 180:599–607. doi:10.1016/j.ajpath.2011.10.036.
   PubMed Web of Science ®Google Scholar
• Liu X, Krawczyk E, Suprynowicz FA, Palechor-Ceron N, Yuan H, Dakic A, Simic V, Zheng YL, Sripadhan P, Chen C, et al. 2017. Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens. Nat Protoc. 12:439–451. doi:10.1038/nprot.2016.174.
   PubMed Web of Science ®Google Scholar
• Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995;47:331–385.
   PubMed Web of Science ®Google Scholar
• Pilch DR, Sedelnikova OA, Redon C, Celeste A, Nussenzweig A, Bonner WM. 2003. Characteristics of gamma-H2AX foci at DNA double-strand breaks sites. Biochem Cell Biol. 81:123–129. doi:10.1139/o03-042.
   PubMed Web of Science ®Google Scholar
• Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. 2001. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem. 276:42462–42467. doi:10.1074/jbc.C100466200.
   PubMed Web of Science ®Google Scholar
• Bakkenist CJ, Kastan MB. 2003. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 421:499–506. doi:10.1038/nature01368.
   PubMed Web of Science ®Google Scholar
• Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A. 2013. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 19:5003–5015. doi:10.1158/1078-0432.CCR-13-1391.
   PubMed Web of Science ®Google Scholar
• Pilot A. Study of Induction PARP Inhibition in Ovarian Cancer. Bethesda (MD): National Library of Medicine; 2014 Dec 15. accessed Sep 2018 https://clinicaltrials.gov/ct2/show/NCT02316834
   Google Scholar
• Pilot trial of BMN 673, an Oral PARP inhibitor, in patients with advanced solid tumors and deleterious BRCA mutations. Bethesda (MD): National Library of Medicine; 2013 Nov 21. accessed 2018 Sep 18 https://clinicaltrials.gov/ct2/show/NCT01989546
   Google Scholar
• DelloRusso C, Welcsh PL, Wang W, Garcia RL, King M-C, Swisher EM. 2007. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol Cancer Res. 5:35–45. doi:10.1158/1541-7786.mcr-06-0234.
   PubMed Web of Science ®Google Scholar
• Hoy SM. 2018. Talazoparib: first global approval. Drugs. 78:1939–1946. doi:10.1007/s40265-018-1026-z.
   PubMed Web of Science ®Google Scholar
• Ison G, Howie LJ, Amiri-Kordestani L, Zhang L, Tang S, Sridhara R, Pierre V, Charlab R, Ramamoorthy A, Song P, et al. 2018. FDA approval summary: niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy. Clin Cancer Res. 24:4066–4071. doi:10.1158/1078-0432.CCR-18-0042.
   PubMed Web of Science ®Google Scholar
• Musella A, Bardhi E, Marchetti C, Vertechy L, Santangelo G, Sassu C, Tomao F, Rech F, D’Amelio R, Monti M, et al. 2018. Rucaparib: an emerging parp inhibitor for treatment of recurrent ovarian cancer. Cancer Treat Rev. 66:7–14. doi:10.1016/j.ctrv.2018.03.004.
   PubMed Web of Science ®Google Scholar
• Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, et al. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 376:245–251. doi:10.1016/S0140-6736(10)60893-8.
   PubMed Web of Science ®Google Scholar
• Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, et al. 2010. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 28:2512–2519. doi:10.1200/jco.2009.26.9589.
   PubMed Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 376:235–244. doi:10.1016/S0140-6736(10)60892-6.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, et al. 2015. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 137:386–391. doi:10.1016/j.ygyno.2015.03.042.
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Carden CR, Roelvink M, De Greve J, Gourley CM, Carmichael J, De Bono JS, Schellens JH, Kaye SB. 2008. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a phase I study. J Clin Oncol. 26:5510. doi:10.1200/jco.2008.26.15_suppl.5510.
   Web of Science ®Google Scholar
• Konstantinopoulos PA, Matulonis UA. 2018. PARP inhibitors in ovarian cancer: a trailblazing and transformative journey. Clin Cancer Res. 24:4062–4065. doi:10.1158/1078-0432.CCR-18-1314.
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–917. nature03443 [pii]. doi:10.1038/nature03443.
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–921. nature03445 [pii]. doi:10.1038/nature03445.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, et al. 2017. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 390:1949–1961. doi:10.1016/S0140-6736(17)32440-6.
   PubMed Web of Science ®Google Scholar
• Drean A, Lord CJ, Ashworth A. 2016. PARP inhibitor combination therapy. Crit Rev Oncol Hematol. 108:73–85. doi:10.1016/j.critrevonc.2016.10.010.
   PubMed Web of Science ®Google Scholar
• Neckers L, Workman P. 2012. Hsp90 molecular chaperone inhibitors: are we there yet?. Clin Cancer Res. 18:64–76. doi:10.1158/1078-0432.CCR-11-1000.
   PubMed Web of Science ®Google Scholar
• Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, et al. 2013. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci USA. 110:17041–17046. doi:10.1073/pnas.1305170110.
   PubMed Web of Science ®Google Scholar
• Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D’Andrea AD, et al. 2016. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 7:13587–13598. doi:10.18632/oncotarget.7277.
   PubMed Web of Science ®Google Scholar
• Choi YE, Battelli C, Watson J, Liu J, Curtis J, Morse AN, Matulonis UA, Chowdhury D, Konstantinopoulos PA. 2014. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget. 5:2678–2687. doi:10.18632/oncotarget.1929.
   PubMedGoogle Scholar
• Johnson N, Cai D, Kennedy RD, Pathania S, Arora M, Li YC, D’Andrea AD, Parvin JD, Shapiro GI. 2009. Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. Mol Cell. 35:327–339. doi:10.1016/j.molcel.2009.06.036.
   PubMed Web of Science ®Google Scholar
• Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, et al. 2011. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med. 17:875–882. doi:10.1038/nm.2377.
   PubMed Web of Science ®Google Scholar
• Lee JW, Lee K-M, Han W. 2013. Abstract C76: foxM1 inhibition sensitized BRCA-proficient triple-negative breast cancer to PARP inhibition. Mol Cancer Ther. 12:C76. doi:10.1158/1535-7163.targ-13-c76.
   Google Scholar
• Picard D. HSP90 interactors. Geneva (Switzerland): University of Geneva; 2018 Aug 4. accessed 2018 Aug 22 http://www.picard.ch/downloads/Hsp90interactors.pdf
   Google Scholar
• Echeverria PC, Bhattacharya K, Joshi A, Wang T, Picard D. 2019. The sensitivity to Hsp90 inhibitors of both normal and oncogenically transformed cells is determined by the equilibrium between cellular quiescence and activity. PLoS One. 14:e0208287. doi:10.1371/journal.pone.0208287.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos P, Palakurthi S, Zeng Q, Zhou S, Liu JF, Ivanova E, Paweletz C, Kommajosyula N, D’Andrea AD, Shapiro G, et al. 2016. In vivo synergism between PARP-inhibitor olaparib and HSP90-inhibitor AT13387 in high grade serous ovarian cancer patient derived xenografts. J Clin Oncol. 34:e17045–e. doi:10.1200/JCO.2016.34.15_suppl.e17045.
   Web of Science ®Google Scholar
• Miyamoto M, Takano M, Aoyama T, Soyama H, Ishibashi H, Kato K, Iwahashi H, Takasaki K, Kuwahara M, Matuura H, et al. 2018. Phenoxodiol increases cisplatin sensitivity in ovarian clear cancer cells through XIAP down-regulation and autophagy inhibition. Anticancer Res. 38:301–306. doi:10.21873/anticanres.12222.
   PubMed Web of Science ®Google Scholar
• Liu Y, Tang J, Liu D, Zhang L, He Y, Li J, Gao L, Tang D, Jin X, Kong D. 2018. Increased autophagy in EOC re-ascites cells can inhibit cell death and promote drug resistance. Cell Death Dis. 9:419. doi:10.1038/s41419-018-0449-5.
   PubMed Web of Science ®Google Scholar
• Wang J, Wu GS. 2014. Role of autophagy in cisplatin resistance in ovarian cancer cells. J Biol Chem. 289:17163–17173. doi:10.1074/jbc.M114.558288.
   PubMed Web of Science ®Google Scholar
• Neckers L, Blagg B, Haystead T, Trepel JB, Whitesell L, Picard D. 2018. Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development. Cell Stress Chaperones. 23:467–482. doi:10.1007/s12192-018-0877-2.
   PubMed Web of Science ®Google Scholar
• Yuno A, Lee MJ, Lee S, Tomita Y, Rekhtman D, Moore B, Trepel JB. 2018. Clinical evaluation and biomarker profiling of Hsp90 inhibitors. Methods Mol Biol. 1709:423–441. doi:10.1007/978-1-4939-7477-1_29.
   PubMedGoogle Scholar
• Kryeziu K, Bruun J, Guren TK, Sveen A, Lothe RA. 2019. Combination therapies with HSP90 inhibitors against colorectal cancer. Biochim Biophys Acta Rev Cancer. 1871:240–247. doi:10.1016/j.bbcan.2019.01.002.
   PubMed Web of Science ®Google Scholar